Can you take Caplacizumab with Ibritumomab?
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- caplacizumab
- ibritumomab
Drug interactions
Major drug interactions
Major:
ibritumomab tiuxetan caplacizumab
Applies to: ibritumomab and caplacizumab
Using ibritumomab tiuxetan together with caplacizumab may increase the risk of bleeding. In clinical studies, treatment with ibritumomab tiuxetan alone has been associated with severe and sometimes fatal hemorrhage.
Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as:
- dizziness
- lightheadedness
- red or black, tarry stools
- coughing up or vomiting fresh or dried blood that looks like coffee grounds
- severe headache
- weakness
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
6 potential interactions Applies to: 6 conditions, including Liver Disease, Leukemia, Myelodysplastic Diseases, Coagulation Defects and Disorders, and Bone Marrow Depression/Low Blood Counts.
Bone Marrow Depression/Low Blood Counts
Major:
ibritumomab
The ibritumomab tiuxetan in ibritumomab has a major potential interaction with Bone Marrow Depression/Low Blood Counts.
The use of ibritumomab tiuxetan may result in severe and prolonged cytopenias. Do not administer the ibritumomab tiuxetan therapeutic regimen to patients with >= 25% lymphoma marrow involvement and/or impaired bone marrow reserve. It is recommended to monitor patients for signs of cytopenia for up to 3 months after treatment and for hematological toxicity including development of myelodysplastic syndrome and/or acute myelogenous leukemia.
Coagulation Defects and Disorders
Moderate:
caplacizumab
Caplacizumab has a moderate potential interaction with Coagulation Defects and Disorders.
Caplacizumab increases the risk of bleeding. This risk is increased in patients with underlying coagulopathies (e.g., hemophilia, other coagulation factor deficiencies). It is also increased with concomitant use of drugs affecting hemostasis and coagulation. Treatment with caplacizumab should be interrupted if clinically significant bleeding occurs. Caution and close monitoring is advised.
Leukemia
Moderate:
ibritumomab
The ibritumomab tiuxetan in ibritumomab has a moderate potential interaction with Leukemia.
The radiation dose resulting from therapeutic exposure to Y-90 radiolabeled ibritumomab tiuxetan may result in secondary malignancies. Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) has been reported in clinical trials with ibritumomab tiuxetan. It is recommended to monitor patients for hematological toxicity including development of MDS or AML.
Liver Disease
Moderate:
caplacizumab
Caplacizumab has a moderate potential interaction with Liver Disease.
No formal studies with caplacizumab have been conducted in patients with severe acute or chronic hepatic impairment and no data regarding the use of the drug in these populations are available. Due to a potential increased risk of bleeding, the use of caplacizumab in patients with severe hepatic impairment requires close monitoring.
Myelodysplastic Diseases
Moderate:
ibritumomab
The ibritumomab tiuxetan in ibritumomab has a moderate potential interaction with Myelodysplastic Diseases.
The radiation dose resulting from therapeutic exposure to Y-90 radiolabeled ibritumomab tiuxetan may result in secondary malignancies. Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) has been reported in clinical trials with ibritumomab tiuxetan. It is recommended to monitor patients for hematological toxicity including development of MDS or AML.
Vaccination
Major:
ibritumomab
The ibritumomab tiuxetan in ibritumomab has a major potential interaction with Vaccination.
The safety of immunization with live viral vaccines following the ibritumomab tiuxetan has not been studied. Do not administer live viral vaccines to patients who have recently received ibritumomab tiuxetan. The ability to generate an immune response to any vaccine following the therapeutic regimen has not been studied.
Report options
More resources
caplacizumab
A total of 166 drugs are known to interact with caplacizumab.
- Caplacizumab is in the drug class platelet aggregation inhibitors.
- Caplacizumab is used to treat Thrombotic Thrombocytopenic Purpura.
ibritumomab
A total of 387 drugs are known to interact with ibritumomab.
- Ibritumomab is in the following drug classes: CD20 monoclonal antibodies, radiologic conjugating agents.
- Ibritumomab is used to treat Non-Hodgkin's Lymphoma.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.